Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZVS 101e

Next Previous
Drug Profile

ZVS 101e

Alternative Names: rAAV2/8-hCYP4V2; rAAV8-hCYP4V2; ZVS-101e

Latest Information Update: 24 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chigenovo
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action CYP4V2 protein replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bietti crystalline dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bietti crystalline dystrophy

Most Recent Events

  • 20 Dec 2024 Phase-III clinical trials in Bietti crystalline dystrophy in China (Intraocular) (NCT06743646)
  • 29 Apr 2023 Adverse events data from a phase I trial in Bietti crystalline dystrophy released by Chinagene
  • 20 Feb 2023 Phase-I/II clinical trials in Bietti crystalline dystrophy in China (Intraocular) (NCT05832684)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top